Denosumab, an anti-RANKL antibody approved by the FDA for the management of osteoporosis and breast and prostate cancer bone metastasis, has been shown to improve or delay skeletal metastasis in breast and prostate cancer by 35% [15] and 18% [16], respectively. Here, TNFSF11 is linked to prostate cancer.